Respiratory Syncytial Virus Inhibitors

Respiratory Syncytial Virus (RSV) is a negative-sense, single-stranded RNA virus belonging to the Paramyxoviridae family. It is a major cause of respiratory tract infections, particularly in infants, young children, and the elderly, often leading to bronchiolitis and pneumonia. The primary target of RSV infection is the respiratory epithelium, where the virus replicates and spreads, causing inflammation and damage to the airway tissues. RSV achieves cell entry through fusion of its envelope with the host cell membrane, facilitated by the fusion (F) protein present on the viral surface. Additionally, RSV possesses attachment (G) and fusion (F) glycoproteins that mediate viral attachment to host cells and facilitate membrane fusion, respectively. The fusion process allows RSV to enter host cells and initiate viral replication, leading to the spread of infection within the respiratory tract.

Inhibition of RSV primarily targets key viral components involved in viral entry, replication, and assembly. Various strategies have been explored to inhibit RSV infection, including the development of antiviral agents targeting viral proteins such as the fusion (F) protein, attachment (G) protein, and RNA-dependent RNA polymerase. Inhibition of the fusion process, either by blocking the interaction between the viral fusion protein and host cell receptors or by impeding the conformational changes necessary for membrane fusion, represents a promising approach to inhibit viral entry and subsequent infection. Additionally, inhibition of viral replication through the targeting of essential viral enzymes, such as the RNA-dependent RNA polymerase, could disrupt viral replication and reduce viral load within infected individuals. Furthermore, modulation of host immune responses and the development of vaccines targeting RSV antigens have also been investigated as strategies to inhibit RSV infection. These approaches collectively aim to disrupt viral replication and transmission, ultimately reducing the burden of RSV-associated respiratory illnesses.